Funder: The Mark Foundation for Cancer Research
Due Dates (Anticipated): February 2026 (Letter of Intent — Intrinsically Disordered Proteins & Cancer RFP) | January 2027 (Letter of Intent — Glioblastoma RFP)
Funding Amounts: Up to $250,000 total for 1 year (standard ASPIRE Award); indirect costs capped at 10% of direct costs; larger amounts possible for clinical studies by invitation.
Summary: Supports high-risk, high-reward cancer research projects from discovery through early clinical studies, with a focus on novel concepts and critical proof-of-concept work.
Key Information: This is a forecasted opportunity; all deadlines are projected and subject to change.